Search

The Harold C. Simmons Comprehensive Cancer Center has been awarded grants from the Cancer Prevention and Research Institute of Texas to increase minority participation in clinical trials, expand lung cancer screening, develop brain tumor drugs, and advance innovations in drug discovery and

Funded by a Specialized Program of Research Excellence (SPORE) award from the National Cancer Institute (NCI), the Kidney Cancer Program (KCP) at UT Southwestern’s Harold C. Simmons Comprehensive Cancer Center reports the largest and most diverse catalog of kidney cancer tumor models to date.

Researchers at UT Southwestern Medical Center studied outcomes for young women at a county hospital and found that while 97% of them accessed prenatal care, those with greater social needs were associated with adverse outcomes both during pregnancy and during the early weeks of their babies’ lives

UT Southwestern researchers have identified the characteristics of more than 100 memory-sensitive neurons that play a central role in how memories are recalled in the brain.

Combining two agents to block a parasitic worm’s life cycle boosted survival from a potentially deadly tropical disease to 85% in animal models, far better than either treatment alone.

A subtle smile emerged on Dr. James Leidner’s face as he envisioned telling people of the unusual contribution he made to mankind’s mission to Mars.

What if the key to aging well lies in reprogramming immune system cells to strengthen them against infections and cancer? Researchers at UT Southwestern are working to find out.

W.A. “Tex” Moncrief Jr., whose extraordinary generosity has and will benefit many generations of Texans by expanding UT Southwestern Medical Center programs in Dallas and especially Fort Worth, as well as surrounding communities, died Dec. 28 at age 101.

Two new studies suggest Medicare’s system of penalizing hospitals if too many patients are readmitted within 30 days should also look at whether the patients were well enough to remain in their home during that time.

The COVID-19 pandemic has led to new rules and expectations for clinical trials.